parkinson's disease retatrutide clinical trial research numbers remain "remarkably" consistent, annual report finds Parkinson's drug therapies in the

Older adults: Standards of medical care in diabetes-2021

Conclusion GLP-1RAs are potent therapies for type 2 diabetes and obesity, but their association with gallbladder disease highlights the need to better understand their effects on bile acid homeostasis and gallbladder function

We also support many clients currently on GLP-1's in optimizing their wellbeing and their results

Over the past five years, this convergence has driven extraordinary optimism that GLP-1s might meaningfully diminish dementia risk and perhaps even alter disease progression trajectory to a greater extent than other common diabetes medications [3]

Average participants lost 24.2% of starting body weight, but individual results ranged from 15.8% to 31.4%

Y., Ahmad, N